PACIRA BIOSCIENCES INC (PCRX) Stock Price, Quote, News and Overview

Company Profile

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 711 full-time employees. The company went IPO on 2011-02-03. The firm's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. The company is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Company Info

PACIRA BIOSCIENCES INC

5401 West Kennedy Boulevard, Suite 890

Tampa FLORIDA 07054 US

CEO: David Stack

Employees: 712

Company Website: https://www.pacira.com/

Investor Relations: https://investor.pacira.com/

Phone: 18135536680